Apellis Pharmaceuticals Inc (APLS) Expected to Announce Earnings of -$0.65 Per Share

Equities analysts expect Apellis Pharmaceuticals Inc (NASDAQ:APLS) to announce earnings of ($0.65) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Apellis Pharmaceuticals’ earnings. Apellis Pharmaceuticals posted earnings of ($0.60) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 8.3%. The business is scheduled to announce its next quarterly earnings report on Monday, March 18th.

On average, analysts expect that Apellis Pharmaceuticals will report full-year earnings of ($2.38) per share for the current fiscal year, with EPS estimates ranging from ($2.41) to ($2.35). For the next fiscal year, analysts forecast that the business will report earnings of ($3.05) per share, with EPS estimates ranging from ($3.24) to ($2.85). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Apellis Pharmaceuticals.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05.

Several research firms have recently weighed in on APLS. Cantor Fitzgerald set a $53.00 price objective on Apellis Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, September 4th. B. Riley lifted their price objective on Apellis Pharmaceuticals from $27.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, September 13th. Citigroup lifted their price objective on Apellis Pharmaceuticals from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, December 6th. Zacks Investment Research raised Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 8th. Finally, ValuEngine raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $38.67.

NASDAQ APLS opened at $16.31 on Friday. The stock has a market capitalization of $954.44 million and a PE ratio of -4.44. Apellis Pharmaceuticals has a 1-year low of $11.45 and a 1-year high of $32.00. The company has a current ratio of 14.90, a quick ratio of 14.91 and a debt-to-equity ratio of 0.14.

In other news, major shareholder Morningside Venture Investment acquired 81,323 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 21st. The shares were acquired at an average cost of $19.48 per share, with a total value of $1,584,172.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.30% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Hillhouse Capital Management Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 203.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 4,328,289 shares of the company’s stock valued at $95,222,000 after buying an additional 2,899,718 shares during the period. venBio Partners L.P. purchased a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter valued at about $72,482,000. BlackRock Inc. raised its holdings in shares of Apellis Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 2,853,195 shares of the company’s stock valued at $50,730,000 after buying an additional 54,227 shares during the period. Vanguard Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after buying an additional 72,610 shares during the period. Finally, Vanguard Group Inc raised its holdings in shares of Apellis Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc now owns 1,414,900 shares of the company’s stock valued at $25,157,000 after buying an additional 72,610 shares during the period. Institutional investors and hedge funds own 55.94% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Featured Article: Why do companies issue stock splits?

Get a free copy of the Zacks research report on Apellis Pharmaceuticals (APLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply